Calidi Biotherapeutics (CLDI)
:CLDI
Want to see CLDI full AI Analyst Report?
CLDI Stock Chart & Stats
$0.18
-$0.04(-2.72%)
At close: 4:00 PM EST
$0.18
-$0.04(-2.72%)
Day’s Range― - ―
52-Week Range$0.16 - $19.20
Previous CloseN/A
Volume567.49K
Average Volume (3M)164.15K
Market Cap
$3.27M
Enterprise Value-$3.61M
Total Cash (Recent Filing)$6.63M
Total Debt (Recent Filing)$1.66M
Price to Earnings (P/E)―
Beta0.75
Next Earnings
Aug 18, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.19
Shares Outstanding19,311,625
10 Day Avg. Volume193,319
30 Day Avg. Volume164,153
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)1.34
Price to Sales (P/S)0.00
P/FCF Ratio-0.24
Enterprise Value/Market Cap-1.10
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit4.34
Enterprise Value/Ebitda0.21
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-5.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical DataEarly clinical data with a single dose of lead agent CLD-101 showed a near doubling of PFS and OS in some glioma patients.
Regulatory ApprovalThe FDA has cleared Northwestern University’s IND application for Calidi’s NeuroNova (CLD-101).
Bears Say
Financial StabilityGiven the company's financial situation, even after the offering, there appears to be meaningful risk to the company continuing as a going concern.
Calidi Biotherapeutics News
CLDI FAQ
What was Calidi Biotherapeutics’s price range in the past 12 months?
Calidi Biotherapeutics lowest stock price was $0.16 and its highest was $19.20 in the past 12 months.
What is Calidi Biotherapeutics’s market cap?
Calidi Biotherapeutics’s market cap is $3.27M.
When is Calidi Biotherapeutics’s upcoming earnings report date?
Calidi Biotherapeutics’s upcoming earnings report date is Aug 18, 2026 which is in 67 days.
How were Calidi Biotherapeutics’s earnings last quarter?
Calidi Biotherapeutics released its earnings results on May 14, 2026. The company reported -$0.43 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.43.
Is Calidi Biotherapeutics overvalued?
According to Wall Street analysts Calidi Biotherapeutics’s price is currently Overvalued.
Does Calidi Biotherapeutics pay dividends?
Calidi Biotherapeutics does not currently pay dividends.
What is Calidi Biotherapeutics’s EPS estimate?
Calidi Biotherapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Calidi Biotherapeutics have?
Calidi Biotherapeutics has 19,311,625 shares outstanding.
What happened to Calidi Biotherapeutics’s price movement after its last earnings report?
Calidi Biotherapeutics reported an EPS of -$0.43 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -2.116%.
Which hedge fund is a major shareholder of Calidi Biotherapeutics?
Currently, no hedge funds are holding shares in CLDI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Calidi Biotherapeutics
Calidi Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on immuno-oncology, dedicated to developing advanced immunotherapies for various cancers. The company's innovative approach centers on utilizing powerful, allogeneic (donor-derived) stem cells as specialized carriers for anti-tumor agents. This technology is being advanced to address a range of oncological conditions, including aggressive brain tumors (high-grade gliomas) and other solid malignancies. Calidi's proprietary cell-based delivery systems are expertly designed to safeguard, amplify, and boost the therapeutic effects of oncolytic viruses. This strategic delivery method aims to achieve superior treatment efficacy and enhance patient safety. The company's clinical pipeline features two primary candidates: NeuroNova, which employs allogeneic neural stem cells loaded with an oncolytic adenovirus specifically for the treatment of high-grade gliomas; and SuperNova, which utilizes allogeneic adipose-derived mesenchymal stem cells to deliver the tumor-selective CAL1 oncolytic vaccinia virus for advanced metastatic solid tumors. Established in 2014, Calidi Biotherapeutics operates out of San Diego, California.
Technical Analysis
Galmed Pharmaceuticals
―
Jaguar Animal Health
―
―
Adial Pharmaceuticals
―
Cardio Diagnostics Holdings
―
Ownership Overview
1.89% Insiders
0.34% Mutual Funds
8.43% Other Institutional Investors
89.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---